Literature DB >> 22291761

Carboxylic acid derivatives of histone deacetylase inhibitors induce full length SMN2 transcripts: a promising target for spinal muscular atrophy therapeutics.

Didem Dayangac-Erden1, Gamze Bora-Tatar, Sevim Dalkara, Ayhan S Demir, Hayat Erdem-Yurter.   

Abstract

INTRODUCTION: Proximal spinal muscular atrophy (SMA) is a common autosomal recessively inherited neuromuscular disorder. It is caused by homozygous absence of the survival motor neuron 1 (SMN1) gene. SMN2, which modulates the severity of the disease, represents a major target for therapy. The aim of this study was to investigate whether SMN2 expression can be increased by caffeic acid, chlorogenic acid and curcumin, which are designed by modifications of the carboxylic acid class of histone deacetylase (HDAC) inhibitors.
MATERIAL AND METHODS: Using quantitative real-time PCR, we analysed the levels of full-length SMN2 and Δ7SMN2 mRNA. We performed LDH cytotoxicity assay to analyse whether SMN2 activating concentrations of caffeic acid, chlorogenic acid and curcumin were cytotoxic to fibroblasts.
RESULTS: We found that caffeic acid and curcumin were more efficient than chlorogenic acid and increased full-length SMN2 mRNA levels 1.5 and 1.7-fold, respectively. Δ7SMN2 mRNA levels were measured to investigate alternative splicing of exon 7. We also found that cytotoxicity was not observed at SMN2 activating concentrations.
CONCLUSIONS: Our data suggest that carboxylic acid derivatives including phenolic structure and symmetry could be a good candidate for SMA treatment.

Entities:  

Keywords:  SMN2 gene; histone deacetylase inhibitors; therapy

Year:  2011        PMID: 22291761      PMCID: PMC3258711          DOI: 10.5114/aoms.2011.22072

Source DB:  PubMed          Journal:  Arch Med Sci        ISSN: 1734-1922            Impact factor:   3.318


Introduction

Autosomal recessive spinal muscular atrophy (SMA) is a leading genetic cause of childhood mortality. Patients develop symmetrical, proximal weakness resulting from neurogenic muscle atrophy. The disease is characterized by selective loss of large α motor neurons in the anterior horn of the spinal cord. Clinically, childhood-onset SMA is classified into three groups (type I: severe, type II: intermediate, type III: mild) according to age of onset and severity [1, 2]. All forms of SMA are caused by the homozygous deletion of the telomeric copy of the survival motor neuron(SMN1) gene on chromosome 5q13 [3-5], which codes the survival motor neuron (SMN) protein [6]. A second gene, centromeric copy of the SMNgene (SMN2) is also located at the same chromosomal region [3]. Because of a silent mutation (C to T) at position + 6 in exon 7, an exonic splicing enhancer (ESE) is destroyed and exon 7 skipping occurs in SMN2 pre-mRNA [7]. In contrast to SMN1, SMN2only produces 10% full-length transcripts (FL-SMN2). Ninety percent of SMN2 transcripts lack exon 7 (Δ7SMN2) and cannot compensate for the loss of SMN1 [8]. SMN2 is considered as the major target for a potential SMA therapy. Increasing SMN2 transcription and changing its splicing pattern are the most effective strategies [9]. Several histone deacetylase (HDAC) inhibitors which increase the expression of the SMN2gene have been described [10-16]. The HDAC inhibitors stimulate acetylation of histones which can relax chromatin structure and enable binding of transcriptional machinery to target genes [17]. They are known to change the expression of 7-10% of genes [18]; but, how they activate SMN2 expression remains unknown. Histone deacetylase inhibitors consist of a metal binding moiety, a capping group and a linker [19]. They are divided into hydroxamates, cyclic tetrapeptides, benzamides, electrophilic ketones and carboxylic acids [20]. The carboxylic acid class such as sodium butyrate, phenylbutyrate and valproic acid is the first investigated HDAC inhibitor group in the treatment of SMA. Their effect has been tested in SMA mouse models and treatment improved motor abilities and reduced neurodegeneration [21]. There are limited structure activity data for carboxylic acids. Therefore, in our previous study we developed new carboxylic acid derivatives by rational design and molecular modifications were made to the functional group, capping group and linker. In addition to the rational design approach, molecular docking which predicts inhibitor activity was used. After interpreting the results obtained from rational design and molecular docking tools, we found that among carboxylic acid derivatives, caffeic acid, chlorogenic acid and curcumin have the highest HDAC inhibition activity in a fluorimetric assay [22]. Since the SMN2 gene is present in all patients, it acts as a modifier gene. Therefore activating the SMN2gene is a promising approach in SMA therapeutics. In this study, we investigated the effect of caffeic acid, chlorogenic acid and curcumin, which have HDAC inhibition activity, on SMN2gene expression.

Material and methods

Cell culture and treatment

Human fibroblast cell line (Coriell Cell Repository, GM03813, 3 years old SMA type I) were cultured in DMEM with 10% FCS, 1% penicillin/streptomycin, 1% L-glutamine. 5 × 105 cells were treated with caffeic acid (20 µM, 50 µM, 100 µM), chlorogenic acid (20 µM, 50 µM, 100 µM) and curcumin (12.5 µM, 20 µM, 25 µM, 50 µM, 100 µM) for 24 h. The concentrations used for the three derivatives were chosen according to the activity of known carboxylic acids [23, 24]. For each experiment complete medium was added as a control.

Quantitative analysis of FL-SMN2 and SMN2Δ7 transcripts

Total RNA was isolated by RNeasy Mini Kit (Qiagen) and the absorbance was detected by NanoDrop ND-1000. 450 ng of RNA was converted to cDNA by Quantitect RT (Qiagen). Real-time RT-PCR was performed in triplicate by the iQ5 Real-Time PCR Detection System (Biorad Lab). 25 µl real-time RT-PCR reaction contained 0.096 µM probe, 0.9 µM of each primer and 12.5 µl of TaqMan Universal Master Mix (Applied Biosystems). The conditions were 10 min at 95°C, and 40 cycles of 15 s at 95°C and 1 min at 60°C. The sequences of primers and TaqMan probes were published by Andreassi et al.[11]. The levels of SMN2 transcripts were quantified by 2–ΔΔCt method and normalized to GAPDH and β-actin (Applied Biosystems). The untreated sample was used as a calibrator. The experiments were repeated twice.

Cytotoxicity assay

Cytotoxicity of compounds was measured using LDH Cytotoxicity Assay Kit II (Biovision). 4 × 104 cells were plated in triplicate and incubated at 5% CO2, 37°C for 24 h. Untreated cells were used as low control and cells treated with lysis solution served as high control. Cytotoxicity was determined after 24 h of compound treatment. Following 30 min of incubation at room temperature, absorbance at 450 nm (reference wavelength was 650 nm) was measured to determine LDH activity. Percentage of cytotoxicity was calculated as the ratio of test sample’s absorbance to high control’s absorbance.

Results

To determine the effect of carboxylic acid derivatives on SMN2 expression and splicing, the SMA fibroblast cell line was treated with caffeic acid (20 µM, 50 µM, 100 µM), chlorogenic acid (20 µM, 50 µM, 100 µM) and curcumin (12.5 µM, 20 µM, 25 µM, 50 µM, 100 µM) for 24 h. The levels of SMN2 mRNA were determined by real-time RT-PCR. All three compounds showed an increase in FL-SMN2 mRNA levels dose dependently (Figure 1). The analysis showed that 20 µM caffeic acid increased FL-SMN2 1.5-fold (Figure 2A). After treatment with chlorogenic acid FL-SMN2 showed a minor increase at 50 µM which was 1.3-fold. However, this increase was not statistically significant compared to the untreated sample (Figure 2B). Interestingly, curcumin, which showed a 1.7-fold significant increase in FL-SMN2 mRNA levels, was regarded as the most efficient among all three derivatives (Figure 2C).
Figure 1

Effect of carboxylic acid derivatives on FL-SMN2 transcript level. SMA fibroblast cell line was treated with chlorogenic acid (50 µM), caffeic acid (20 µM) and curcumin (20 µM) for 24 h. Error bars represent standard deviation

*p < 0.05 shows significant difference in treated compared to untreated

Figure 2

Real-time RT-PCR analysis of FL and Δ7SMN2 transcripts following treatment with caffeic acid (A), chlorogenic acid (B), curcumin (C) at increasing concentrations for 24 h. Error bars represent standard deviation

*p < 0.05 shows significant difference in treated compared to untreated

To investigate whether caffeic acid, chlorogenic acid and curcumin influence alternative splicing of exon 7, we also studied the effect of three compounds on the synthesis of Δ7SMN2 mRNA levels. In experiments with caffeic acid, no increase in Δ7SMN2 mRNA levels were observed. The ratio of FL to Δ7 mRNA levels increased by almost 2-fold between 0 µM and 50 µM (Figure 2A). The treatment with chlorogenic acid resulted in an increase in only Δ7SMN2 mRNA levels, suggesting that chlorogenic acid may work through a different mechanism for SMN2 exon 7 inclusion (Figure 2B). We found that curcumin increased both FL and Δ7SMN2 mRNA levels at 12.5 µM and 20 µM. The FL/Δ7 mRNA level remained constant between 12.5 µM and 20 µM but increased between 50 µM and 100 µM (Figure 2C). We performed an LDH cytotoxicity assay to analyse whether SMN2 activating concentrations (20-50 µM) of caffeic acid, chlorogenic acid and curcumin were cytotoxic to fibroblasts. The absorbance of the samples is shown in Figure 3. We found that cytotoxic effects were not detectable and cell viability was 100%.
Figure 3

LDH cytotoxicity assay of chlorogenic acid (50 µM), caffeic acid (20 µM) and curcumin (20 µM) on SMA fibroblast cell line. Cytotoxicity was calculated at SMN2 activating concentrations according to the manufacturer's protocols. Low control: 0.380, high control: 1.87. Error bars represent standard error

Discussion

Recently HDAC inhibitors have been shown to play a role in the treatment of some genetic diseases and also have neuroprotective properties [25]. Therefore they are regarded as candidates for neurodegenerative diseases such as SMA. The disease severity is changed according to functional FL mRNA produced from the SMN2 gene. Therefore increasing SMN2 gene expression has an important role in therapy. The HDAC inhibitors could increase SMN2 gene expression either by directly increasing acetylation at the promoter or changing the acetylation of a transcription factor that indirectly binds the promoter. Alternatively, HDAC inhibition could change the expression of splicing proteins that increase exon 7 inclusion [12]. The HDAC inhibitors have a common pharmacophore which consists of three components. The metal-binding functional group coordinates binding to the Zn++. The hydrocarbon linker fills out the narrow tunnel, and the capping group interacts with the amino acids near the active site [19]. The design of the new inhibitors is based on the modification of the functional group, capping group and the linker. Carboxylic acid derivatives were modified by insertion of hydroxyl and/or carboxylic groups into the alkyl chain or phenyl ring. As we reported previously, after screening a panel of carboxylic acid derivatives, caffeic acid, chlorogenic acid and curcumin were shown to have the highest HDAC inhibition activity [22]. In our current study, we analysed whether these three compounds produced increased amounts of FL-SMN2 transcript. Caffeic acid is a polyphenol that occurs in fruits, wine and coffee. It has been shown to have antioxidant, antiinflammatory, antimetastatic and anti-tumour effects [26]. Real-time RT-PCR results showed that FL transcript levels were increased 1.5-fold after caffeic acid treatment. Previous studies indicated that among carboxylic acids, phenylbutyrate and valproic acid increased FL transcript levels between 1.3-1.6 and 1.2-1.5-fold, respectively, in SMA fibroblasts, which is consistent with our data [11-13]. We also found that Δ7SMN2 transcript levels were reduced and the ratio of FL to Δ7 mRNA levels was increased at some concentrations. The increase in FL to Δ7 ratio indicates that caffeic acid may reverse the SMN2 splicing pattern and prevent exon 7 skipping. Enhanced expression of splicing factors that stimulate exon 7 inclusion could be an explanation for this reversion. By keeping the 4-vinylbenzene-1,2-diol main structure of caffeic acid, two caffeic acid derivatives were chosen. The first derivative, which is chlorogenic acid, is an ester of caffeic acid. We detected a 1.3-fold minor increase in FL-SMN2 transcript levels, which was not statistically significant. It may be speculated that the loss of activity is probably the reason for steric hindrance of the polyfunctional cyclohexane ring. The second derivative, curcumin, the twin structure of caffeic acid, is found in the Indian curry spice turmeric and shows anti-inflammatory and antioxidant activities [27, 28]. It has been shown that curcumin inhibits proliferation of cells and induces cell cycle arrest or apoptosis in various types of cancers [29]. Cell signal pathways and protein kinases including NF-κB, AKT, mitogen-activated protein kinase, STAT, COX-2 and LOX have been reported as targets for curcumin [30-32]. The mechanism of curcumin in SMA treatment has not been determined but studies showed that multiple activities of curcumin are involved in the neuroprotective effect of the compound [33]. Following treatment, we found that curcumin showed the highest increase in FL-SMN2 transcript levels among all compounds, which was detected as 1.7-fold. The reason for increased activity may be symmetry in the curcumin molecule. On the other hand, the level of FL-SMN2 at 50 µM, and the level of FL-SMN2 and Δ7SMN2 at 100 µM were decreased. In the context of enzyme kinetics this decrease may suggest that saturation is achieved gradually between HDAC enzyme and its ligand curcumin. We conclude that the molecular structure of curcumin is the one best fitting the HDAC enzyme active site. Therefore it may be speculated that two phenolic hydroxyl groups and a free carboxylic acid group are not crucial for good interaction with the HDAC enzyme since caffeic acid and chlorogenic acid have one of these two groups. But probably a p-hydroxy group is necessary for hydrogen bonds and an enon group for reversible electrostatic interactions with HDAC enzymes. Similar to our results, Sakla et al.[24] also treated GM03813 cell lines with polyphenols and examined them by RT-PCR. They reported that compounds increase exon 7 inclusion of SMN2 transcripts. We also detected an increase in Δ7SMN2 transcript levels and the ratio of FL to Δ7 mRNA levels remained constant. This increase in both isoforms may be explained by SMN2 promoter activation. However, detecting an increase in FL/Δ7 mRNA levels between 50 µM and 100 µM treatment suggests that curcumin may also prevent exon 7 skipping. Our data show that curcumin increases FL-SMN2 transcript by not only activating the promoter, but also splicing. On the basis of these observations, further experiments are being planned on caffeic acid and curcumin to investigate their effect on SMN2 protein. Western blot analysis combined with real-time RT-PCR results will provide more information about the mechanism of the compounds’ effect on SMN2 expression. In recent years, phenolic compounds have become popular for protection against degenerative diseases including SMA [33]. The phenolic structure and replication of the molecule, as demonstrated in curcumin, can be one of the strategies to design novel HDAC inhibitors in the treatment of SMA. In conclusion, in this study, we found that among carboxylic acid derivatives, caffeic acid and curcumin increase the level of FL-SMN2 mRNA in SMA fibroblasts, indicating that they can be potential candidates in the treatment of SMA. Future studies will aim for rational design by keeping the phenolic structure and symmetry of HDAC inhibitors.
  32 in total

1.  The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells.

Authors:  Markus Riessland; Lars Brichta; Eric Hahnen; Brunhilde Wirth
Journal:  Hum Genet       Date:  2006-05-25       Impact factor: 4.132

Review 2.  The neurobiology of childhood spinal muscular atrophy.

Authors:  T O Crawford; C A Pardo
Journal:  Neurobiol Dis       Date:  1996-04       Impact factor: 5.996

3.  In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy.

Authors:  Eric Hahnen; Ilker Y Eyüpoglu; Lars Brichta; Kirsten Haastert; Christian Tränkle; Florian A Siebzehnrübl; Markus Riessland; Irmgard Hölker; Peter Claus; Johann Romstöck; Rolf Buslei; Brunhilde Wirth; Ingmar Blümcke
Journal:  J Neurochem       Date:  2006-07       Impact factor: 5.372

4.  Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes.

Authors:  Abdelhamid Liacini; Judith Sylvester; Wen Qing Li; Muhammad Zafarullah
Journal:  Matrix Biol       Date:  2002-04       Impact factor: 11.583

5.  A novel nuclear structure containing the survival of motor neurons protein.

Authors:  Q Liu; G Dreyfuss
Journal:  EMBO J       Date:  1996-07-15       Impact factor: 11.598

6.  Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: complete regression of hepatoma growth and metastasis by dual mechanism.

Authors:  Tae-Wook Chung; Sung-Kwon Moon; Young-Chae Chang; Jeong-Heon Ko; Young-Choon Lee; Gun Cho; Soo-Hyun Kim; Jong-Guk Kim; Cheorl-Ho Kim
Journal:  FASEB J       Date:  2004-11       Impact factor: 5.191

7.  Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells.

Authors:  Yan Chen; Wenxiu Shu; Weihua Chen; Qing Wu; Hongli Liu; Guohui Cui
Journal:  Basic Clin Pharmacol Toxicol       Date:  2007-10-09       Impact factor: 4.080

8.  Induction of full-length survival motor neuron by polyphenol botanical compounds.

Authors:  Mary S Sakla; Christian L Lorson
Journal:  Hum Genet       Date:  2007-10-26       Impact factor: 4.132

9.  Deletions in the survival motor neuron gene on 5q13 in autosomal recessive spinal muscular atrophy.

Authors:  N R Rodrigues; N Owen; K Talbot; J Ignatius; V Dubowitz; K E Davies
Journal:  Hum Mol Genet       Date:  1995-04       Impact factor: 6.150

10.  Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy.

Authors:  Amy M Avila; Barrington G Burnett; Addis A Taye; Francesca Gabanella; Melanie A Knight; Parvana Hartenstein; Ziga Cizman; Nicholas A Di Prospero; Livio Pellizzoni; Kenneth H Fischbeck; Charlotte J Sumner
Journal:  J Clin Invest       Date:  2007-02-22       Impact factor: 14.808

View more
  6 in total

Review 1.  Developing therapies for spinal muscular atrophy.

Authors:  Mary H Wertz; Mustafa Sahin
Journal:  Ann N Y Acad Sci       Date:  2015-07-14       Impact factor: 5.691

2.  Multiple effects of curcumin on promoting expression of the exon 7-containing SMN2 transcript.

Authors:  Dairong Feng; Yi Cheng; Yan Meng; Liping Zou; Shangzhi Huang; Jiuyong Xie
Journal:  Genes Nutr       Date:  2015-09-19       Impact factor: 5.523

3.  Caffeic acid phenethyl ester induces adrenoleukodystrophy (Abcd2) gene in human X-ALD fibroblasts and inhibits the proinflammatory response in Abcd1/2 silenced mouse primary astrocytes.

Authors:  Jaspreet Singh; Mushfiquddin Khan; Inderjit Singh
Journal:  Biochim Biophys Acta       Date:  2013-01-11

4.  In vitro Cytotoxic Activities and Molecular Mechanisms of Angelica shikokiana Extract and its Isolated Compounds.

Authors:  Amira Mira; Kuniyoshi Shimizu
Journal:  Pharmacogn Mag       Date:  2015-10       Impact factor: 1.085

Review 5.  Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy.

Authors:  Jafar Mohseni; Z A M H Zabidi-Hussin; Teguh Haryo Sasongko
Journal:  Genet Mol Biol       Date:  2013-08-30       Impact factor: 1.771

6.  Investigations of curcumin and resveratrol on neurite outgrowth: perspectives on spinal muscular atrophy.

Authors:  Gamze Bora-Tatar; Hayat Erdem-Yurter
Journal:  Biomed Res Int       Date:  2014-07-02       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.